A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Clinical trial NCT04750278 · TERMINATED

Trial details

NCT number: NCT04750278
Sponsor: Foresee Pharmaceuticals Co., Ltd.
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Severe to Critical COVID 19 With Associated ARDS

Start date: 2021-04-06
Primary completion: 2022-04-18
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.